Biomarker update for breast, colorectal and non-small cell lung cancer.
The integration of diagnostics into the selection, administration, dosing and monitoring of the use of anticancer drugs has continued to impact the pharmaceutical industry with particular emphasis on cancers of the breast, colon and lung. An update is given on the biomarkers for these cancers.
Ross
Jeffrey S
JS
Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA. rossj@mail.amc.edu
D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000175:diagnosis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis*; D015179:Colorectal Neoplasms / Q000175:diagnosis*; D066246:ErbB Receptors / Q000032:analysis / Q000235:genetics; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis*; D009154:Mutation; D009360:Neoplastic Cells, Circulating; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human